MMSI Stock Forecast & Price Target

Merit Medical Systems is well positioned for sustained outperformance because it is tracking toward or above its 2024E-2026E Continued Growth Initiatives targets, with consensus implying a 6.6% organic revenue CAGR, a 2026E adjusted operating margin of 21.2%, and cumulative free cash flow of $634M versus a $400M goal. Its appeal is reinforced by 1Q26 results that beat consensus, including $382M of revenue, 3.7% organic growth, EPS of $0.94, and a 19.7% operating margin despite tariff pressure, showing resilient execution and operating leverage. Longer term, management’s shift toward higher-growth therapeutic products, new launches like WRAPSODY, and disciplined margin expansion support double-digit EPS growth and strong cash generation.

Merit Medical Systems is facing a weakening fundamental setup as organic revenue growth slowed to 2.7% in 1Q26, with OEM sales down 14% Y/Y and international growth lagging at about 3% Y/Y, while recent acquisitions and new product launches appear unlikely to offset the deceleration. Management’s maintained 2026 free cash flow guidance of at least $200M is respectable, but the bear case implies 5% or lower revenue growth and further operating margin contraction, which would pressure below-consensus earnings. Although the balance sheet remains workable with $488M of cash, $748M of long-term debt, and 1.6x net leverage, execution risk, margin pressure, and slower growth in China could keep the stock under fundamental strain.